Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma
Pancreatic cancer remains a highly malignant and challenging tumor with a dismal 5-year survival rate of only 13%. The majority of patients are diagnosed at advanced stages, where surgical options are limited, and prognosis is poor. Immunotherapy, particularly PD-1 inhibitors, has shown limited succ...
Saved in:
Main Authors: | Hongying Liu, Yun Wang, Qian Zhang, Nengwen Ke |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1458517/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quantification of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab: case reports
by: Kevin Y. Li, et al.
Published: (2024-12-01) -
Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas
by: Jing Chen, et al.
Published: (2024-10-01) -
Primary pancreatic hepatoid carcinoma: A case report
by: Shizheng Mi, et al.
Published: (2025-02-01) -
Comprehensive analysis of the expression and prognostic value of ARMCs in pancreatic adenocarcinoma
by: Guanxiang Zhuo, et al.
Published: (2025-01-01) -
Immune regulatory genes impact the hot/cold tumor microenvironment, affecting cancer treatment and patient outcomes
by: Mengmeng Sang, et al.
Published: (2025-01-01)